Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial
Author:
Shi Min, Zeng Dongqiang, Luo Huiyan, Xiao Jian, Li Yongqiang, Yuan Xia, Huang Na, Wu Jiani, Zheng Siting, Wu Jianhua, Li Shaowei, Rong Xiaoxiang, Wang Chunlin, Jiang Luyang, Mao Qianqian, Qiu Wenjun, Guo Jian, Deng Qiong, Sun Huiying, Lu Xiansheng, Yu Yunfang, Lai Yonghong, Fang Yiran, Zhou Rui, Wang Ling, Huang Xiatong, Kong Yuyun, Li Jun, Liang Li, Bin Jianping, Liao Yulin, Liao WangjunORCID
Reference48 articles.
1. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer;Shitara;Nature,2022 2. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial;Shitara;Lancet (London, England),2018 3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet (London, England),2017 4. Current developments in gastric cancer: from molecular profiling to treatment strategy;Alsina;Nat. Rev. Gastroenterol. Hepatol.,2023 5. The immune microenvironment in gastric adenocarcinoma;Zavros;Nat. Rev. Gastroenterol. Hepatol.,2022
|
|